article thumbnail

DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes

Physician's Weekly

WEDNESDAY, June 18, 2025 (HealthDay News) — The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in people with diabetes, according to a study published online June 9 in JAMA Internal Medicine. Pilla, M.D.,

article thumbnail

Fecal Microbiota Transplantation Could Be First-Line Therapy for C. Difficile

Physician's Weekly

WEDNESDAY, June 25, 2025 (HealthDay News) — Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI), according to a study published online June 17 in the Annals of Internal Medicine. The groups did not have any significant differences in adverse events.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 242: WDx #17 – “The Next Play”

The Clinical Problem Solvers

Uttara (Tara) Gadde Uttara (Tara) Gadde is an internal medicine resident at the University of Pennsylvania. Aimee K Zaas Aimee K Zaas MD MHS is a Professor of Medicine in the Division of Infectious Diseases in the Department of Medicine at Duke University School of Medicine. in Human Biology, Health & Society.

article thumbnail

Geriatric Medicine Board Meeting Summary | Spring 2025

ABIM

McDonald shared more about a pilot model announced last year that would create a pathway for exceptionally qualified international medical graduates (IMGs) successfully completing ACGME-accredited subspecialty fellowship to become Board eligible in Internal Medicine and subspecialties.

article thumbnail

ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes

Physician's Weekly

Mild-to-moderate gastrointestinal events were the most common adverse events with orforglipron. From baseline to week 40, the percent change in body weight was −4.5, −5.8, percent with the 3-mg, 12-mg, and 36-mg doses, respectively, and −1.7 percent with placebo.

article thumbnail

FDA Approves Polypill Widaplik for Hypertension

Physician's Weekly

The FDA approval is based on positive results from two international phase 3 trials that compared Widaplik to dual combinations of its component drugs as well as to placebo. The most common adverse event reported in patients treated with Widaplik was symptomatic low blood pressure.

article thumbnail

Dr. Logan Gladney: Heart Health Risk Assessment

Boulder Medical Center

What is your risk of having a major cardiovascular event such as a heart attack or stroke? Internist Logan Gladney, MD, shares tools that are used to assess heart disease. The post Dr. Logan Gladney: Heart Health Risk Assessment appeared first on Boulder Medical Center.

Medical 130